

FORM 51-102F3
MATERIAL CHANGE REPORT

ITEM 1 NAME AND ADDRESS

*Datinvest International Ltd. (the “Company”)
Suite 918, 1030 West Georgia Street
Vancouver, British Columbia, V6E 2Y3*

ITEM 2 DATE OF MATERIAL CHANGE

June 6, 2018

ITEM 3 NEWS RELEASE

The Company issued a news release on June 11, 2018 relating to the material change, which was disseminated through Stockwatch and subsequently filed on SEDAR.

ITEM 4 SUMMARY OF MATERIAL CHANGE

The Company entered into a definitive amalgamation agreement with Exxel Pharma Inc. (“Exxel Pharma”), pursuant to which Exxel Pharma has agreed to amalgamate with a wholly-owned subsidiary of the Company.

ITEM 5 FULL DESCRIPTION OF MATERIAL CHANGE

See attached news release.

ITEM 6 RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102

Not applicable. This report is not being filed on a confidential basis.

ITEM 7 OMITTED INFORMATION

Not applicable.

ITEM 8 EXECUTIVE OFFICER

The following executive officer of the Company is knowledgeable about the material change and this report:

*Emily Davis, Corporate Secretary
Telephone: 604.628.5616*

ITEM 9 DATE OF REPORT

June 11, 2018